Millendo Therapeutics (NASDAQ:MLND) Shares Down 9.1%

Millendo Therapeutics, Inc. (NASDAQ:MLND) dropped 9.1% during mid-day trading on Tuesday . The company traded as low as $2.16 and last traded at $2.21. Approximately 589,122 shares traded hands during trading, a decline of 32% from the average daily volume of 865,472 shares. The stock had previously closed at $2.43.

MLND has been the topic of a number of recent analyst reports. SVB Leerink downgraded shares of Millendo Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $5.00 to $2.00 in a report on Wednesday, January 6th. Zacks Investment Research downgraded shares of Millendo Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 13th. Finally, LADENBURG THALM/SH SH downgraded shares of Millendo Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, January 6th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $3.67.

The stock’s 50-day simple moving average is $2.09 and its two-hundred day simple moving average is $1.84. The company has a market capitalization of $41.99 million, a price-to-earnings ratio of -1.00 and a beta of 1.12.

Large investors have recently bought and sold shares of the business. Schonfeld Strategic Advisors LLC acquired a new position in Millendo Therapeutics during the third quarter worth $52,000. Bank of New York Mellon Corp acquired a new stake in shares of Millendo Therapeutics in the fourth quarter valued at about $121,000. JPMorgan Chase & Co. raised its position in shares of Millendo Therapeutics by 8,328.2% in the fourth quarter. JPMorgan Chase & Co. now owns 75,264 shares of the company’s stock valued at $161,000 after buying an additional 74,371 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in shares of Millendo Therapeutics in the third quarter valued at about $297,000. Finally, Barclays PLC raised its position in shares of Millendo Therapeutics by 355.7% in the fourth quarter. Barclays PLC now owns 464,390 shares of the company’s stock valued at $994,000 after buying an additional 362,487 shares during the last quarter. Institutional investors own 41.11% of the company’s stock.

Millendo Therapeutics Company Profile (NASDAQ:MLND)

Millendo Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women.

Read More: Trade Deficit

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.